France fines Johnson & Johnson 25m euros for blocking generic drug


US pharmaceutical firm Johnson & Johnson was found by the French competition agency of deliberately hindering generic production of its painkiller Durogesic.

Reading articles is for subscribers only. Subscribe now.

France's competition authority fined US healthcare group Johnson & Johnson 25 million euros ($29.62 million) on Wednesday after it found the company had deliberately slowed market access to generic copies of its painkiller Durogesic, reports CNBC.